Erythroderma is a rare, potentially life-threatening presentation of psoriasis 
that can be triggered by medication reactions. Bupropion is indicated for major 
depressive disorder (Wellbutrin®, GlaxoSmithKline, Research Triangle Park, NC), 
smoking cessation (Zyban®, GlaxoSmithKline, Research Triangle Park, NC), and 
weight loss (when in formulation with naltrexone ER; Contrave®, Orixegen 
Therapeutics, La Jolla, CA). Bupropion can exacerbate psoriasis, however, this 
is an under-recognized side effect of the medication, particularly in the United 
States. We report a case of bupropion-induced erythrodermic psoriasis in a 
62-year-old female who was prescribed the medication for depression. Due to the 
common comorbidities of depression, obesity, and tobacco abuse in psoriatic 
patients, all for which treatment with bupropion is indicated, it is important 
for physicians to be aware of the potential for a life-threatening medication 
reaction in this patient population.